2种方案治疗儿童咳嗽变异性哮喘的疗效及药物经济学评价

The Efficacy and Pharmacoeconomic of Different Treatments Evaluation for Children with Cough Variant Asthma

目的:探讨2种不同方案治疗儿童咳嗽变异性哮喘的疗效及药物经济学。方法:采用回顾性分析方法,纳入本院2019年1~12月进行治疗的4~6岁咳嗽变异性哮喘患儿420例。依据不同治疗方案分为A、B两组,其中A组269例,应用丙酸氟替卡松吸入气雾剂治疗;B组151例,应用沙美特罗替卡松粉吸入剂治疗。分析患儿的治疗效果、肺功能指标、不良反应、成本效果(C/E)、敏感性。结果:A、B两组总有效率分别为95.54%、93.37%,A组稍高于B组,两组间无统计学差异(P>0.05);经治疗两组间患儿肺功能指标改善情况和不良反应对比,均无统计学差异(P>0.05);A组和B组C/E分别为19.72和23.53,△C/△E为-144.23,A组C/E低于B组;当药品价格下降10%时,A组和B组C/E分别为19.00和22.47,△C/△E为-130.23,A组C/E低于B组。结论:儿童咳嗽变异性哮喘,应用丙酸氟替卡松吸入气雾剂治疗效果较好,药物经济学价值较高。

Objective:To explore the efficacy and pharmacoeconomic of 2 different treatments for children with cough variant asthma.Methods:A retrospective study was used to include 420 children with cough variant asthma aged 4-6 years who were treated in our hospital from January to December 2019.According to different treatments,they were divided into groups A and B.Among them,269 patients in group A were treated with fluticasone,151 patients in group B were treated with salmeterol fluticasone.The treatment effect,lung function indexes,adverse reactions,cost-effectiveness(C/E)and sensitivity of the children were analyzed.Results:The curative effects of group A and group B were 95.54%and 93.37%respectively.The total effective rate of group A was higher than that of group B,but there was no statistical difference(P>0.05).There was no statistically significant difference in the improvement of pulmonary function indexes and adverse reactions between the two groups after treatment(P>0.05).The C/E of Group A and Group B were 19.72 and 23.53,△C/△E was-144.23,and the C/E of Group A was lower than that of Group B.When the drug price dropped by 10%,the C/E of Group A and Group B were 19.00 and 22.47,△C/△E was-130.23,and the C/E of Group A was lower than that of Group B.Conclusion:Children with cough variant asthma,treated with fluticasone propionate inhalation aerosol,has good effect and high pharmacoeconomic value.